[Experimental data on the toxicity of nonachlazine, a new antianginal agent].
The results obtained by a study of acute and chronic toxicity of nonachlazine--a new original coronary-active agent endowed with antianginal properties are reported. Nonachlazine has been found to have a sufficiently wide range of therapeutic action. With its repeated (for 36 days) oral introduction to rats in an effective dose of 10 mg/kg the drug does not produce any adverse effect on the general condition of the animals, reduces but insignificantly their weight gain, fails to exert any damaging effect on the blood system, does not change biochemical characteristics featuring the function of the liver, nor evokes any pathohistological changes of the internal organs. Nonachlazine has no locally irritating effect on the gastro-intestinal tract and is a compound producing but a slight stress action.
D000787:Angina Pectoris / Q000517:prevention & control; D000818:Animals; D001769:Blood / Q000187:drug effects; D001772:Blood Cell Count; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D008099:Liver / Q000187:drug effects; D051379:Mice; D010640:Phenothiazines / Q000633:toxicity*; D010879:Piperazines / Q000633:toxicity*; D051381:Rats; D013997:Time Factors; D014665:Vasodilator Agents / Q000633:toxicity*
D010640:Phenothiazines; D010879:Piperazines; D014665:Vasodilator Agents
Eksperimental'nye dannye o toksichnosti nonakhlazina--novogo antianginalinogo sredstva